No Data
US Stock MarketDetailed Quotes
SAGE Sage Therapeutics
Watchlist
19.580
+0.100+0.51% Close 11/30 16:00 ET
19.5800.0000.00%
Post 16:09 ET
20.155High19.460Low646.92KVolume
19.760Open19.480Pre Close12.72MTurnover1.37%Turnover RatioLossP/E (TTM)1.17BMarket Cap59.99052wk HighLossP/E (Static)59.97MShares16.51552wk Low1.44P/B926.66MFloat Cap195.970Historical High--Dividend TTM47.33MShs Float16.515Historical Low--Div YieldTTM3.57%Amplitude19.663Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Sage Therapeutics Company
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Product revenue, net7.69M100.00%
News
Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited
New York, USA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - Sage
Hold Rating on SAGE Therapeutics: Disappointing Zurzuvae Pricing and Uncertain Regulatory Path
SAGE Therapeutics (SAGE) Receives a Hold From Truist Financial
Comments
ColumnsToday's Pre-Market Stock Movers And Top Ratings: UBS, DG, VSCO, PLTR and More
Pre-Market Stock Movers
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
24
1
8/8 Watchlist ⚡️
$Apellis Pharmaceuticals(APLS.US$$Alteryx(AYX.US$$Barfresh Food(BRFH.US$$Celanese Corp(CE.US$$Chegg(CHGG.US$$Chewy(CHWY.US$$Extra Space Storage Inc(EXR.US$$Five9(FIVN.US$$International Flavors & Fragrances(IFF.US$$Lucid Group(LCID.US$$Paramount Global-B(PARA.US$$Sage Therapeutics(SAGE.US$$ShockWave Medical(SWAV.US$$Teradata Corp(TDC.US$$VistaGen Therapeutics(VTGN.US$$Wynn Resorts(WYNN.US$
follow for daily watchlist 🚀
follow for daily watchlist 🚀
3
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
taijahmed75OP : Adding the link here: These Five Biotech Stocks Are Developing Potentially Groundbreaking Mental Health Treatments